Showing 401 results

Filters Content type: News, Editors' picks Topic: Changing treatment

A change of HIV treatment may be necessary because of side-effects, the development of drug resistance, treatment not being fully effective or because of interactions between HIV drugs and other medications.

Changing treatment

Caveat emptor: Seven things every patient should know about switching from efavirenz to dolutegravir

Editor's pick
Spotlight
25 November 2019
Treatment simplification strategies

Options for two-drug simplification expand

News
14 November 2019
Treatment simplification strategies

Jitters Over New Two-Drug HIV Regimens

Editor's pick
Medscape (requires free registration)
12 November 2019
Side effects

Weight gain after switching to integrase inhibitor treatment is small in Dutch and Swiss cohorts

News
11 November 2019
Bone & joint problems

Switching from TDF to TAF associated with improvements in bone mineral density in people over 60

News
4 November 2019
Viral load

Point-of-care viral load testing results in more switches from failing treatment

News
26 September 2019
Changing treatment

FDA Expands Indications for Pifeltro and Delstrigo for HIV

Editor's pick
Medscape (requires free registration)
23 September 2019
Cardiovascular disease

Switching Back to Older Tenofovir Improves Lipid Levels

Editor's pick
POZ
12 September 2019
Changing treatment

‘Alarming’ rates of second-line HIV treatment failure in sub-Saharan Africa

Editor's pick
Avert
22 August 2019
Adherence

Directly observed therapy can be a useful tool in caring for people with HIV treatment failure

News
13 August 2019
Kidney problems

Change in Kidney Function After TDF-to-TAF Switch: Who Benefits Most?

Editor's pick
NATAP
10 August 2019
Changing treatment

High efficacy from switching to bictegravir/F/TAF in virally suppressed participants – including analyses by baseline drug resistance

Editor's pick
i-Base
2 August 2019
HIV treatment for children & young people

Without frequent viral load monitoring dolutegravir-based regimens not the best choice for African youth on failing ART

News
30 July 2019
Changing treatment

Biktarvy Suppresses HIV Well in Women and Those With Drug Resistance

Editor's pick
POZ
29 July 2019
People with limited treatment options

Fostemsavir salvage therapy continues to look good at 96 weeks

News
29 July 2019
Treatment simplification strategies

Dolutegravir dual therapy works well for both first line and maintenance treatment

News
29 July 2019
Treatment simplification strategies

Four days on, three days off HIV treatment as effective as continuous therapy, French study finds

News
25 July 2019
Pharmaceutical industry

GSK touts new Dovato switching data. Is it enough to shake Gilead's HIV lead?

Editor's pick
FiercePharma
11 July 2019
Changing treatment

Drug-Resistance Mutations May Curb Efficacy of Dolutegravir-Based Regimens in Zimbabwe Teens With HIV

Editor's pick
Medscape (free registration required)
7 July 2019
New & experimental HIV treatments

1 Year After Approval: How Does D/C/F/TAF Measure Up?

Editor's pick
Contagion Live
1 July 2019
People with limited treatment options

ART for treatment-experienced people with virological failure can omit NRTIs if three active drugs available

News
13 June 2019
Health monitoring in resource-limited settings

Significant health gains from faster switching to second-line ART in sub-Saharan Africa

News
29 May 2019
Treatment simplification strategies

ViiV Healthcare announces Juluca (dolutegravir/rilpivirine) maintains HIV viral suppression at 148-weeks

Editor's pick
ViiV press release
5 April 2019
Changing treatment

Dolutegravir-based second-line ART achieves excellent virological outcomes even in the presence of resistance to recycled NRTIs

News
13 March 2019